DelveInsight’s report, “Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of colorectal cancer (CRC). The report covers historical and projected epidemiology and highlights market trends across key regions, including the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
To Know in detail about the Colorectal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Colorectal Cancer Market Forecast
Some of the key facts of the Colorectal Cancer Market Report:
-
The Colorectal Cancer (CRC) market is projected to grow at a notable CAGR during the period 2020–2034. Colorectal cancer is the third most commonly diagnosed cancer worldwide. In 2024, the United States is expected to report approximately 106,600 new cases, making CRC the second leading cause of cancer-related deaths among both men and women. In 2023, the total market size for CRC across the seven major markets (7MM) was estimated at around USD 13 billion, with a projected CAGR of about 5% from 2020 to 2034.
-
Within the EU4 and the UK, Germany is expected to hold the largest revenue share in 2034, followed by the UK. According to DelveInsight’s analysis, nearly 40% of new CRC cases in the U.S. were diagnosed as metastatic. In 2023, the most common mutation type in the U.S. was Microsatellite Stable (MSS).
-
Recent treatment advancements include the FDA approval of Takeda’s FRUZAQLA in November 2023 for adults with metastatic CRC who had previously undergone certain chemotherapy and targeted therapies. In April 2024, ENHERTU was approved as the first tumor-agnostic HER2-targeted therapy for patients with metastatic HER2-positive solid tumors, including CRC. In June 2024, Bristol Myers Squibb received accelerated approval for KRAZATI (adagrasib) combined with cetuximab for previously treated KRAS G12C-mutated locally advanced or metastatic CRC.
-
In October 2024, the FDA extended the review of Amgen’s LUMAKRAS (sotorasib) as a second-line CRC treatment by three months, delaying a final decision to January of the following year, which temporarily reduces competitive pressure on KRAZATI.
-
In 2023, the U.S. accounted for approximately 30% of CRC cases across the 7MM, with around 68,400 cases in individuals aged 65–84 years. Additionally, about 52,000 cases were localized in the right colon. Among stage-specific cases in the U.S., localized CRC represented the largest proportion.
-
Key Companies: Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris Biotherapeutics, and others.
-
Key Therapies: FRUZAQLA (fruquintinib), TUKSYA (tucatinib), ENHERTU (trastuzumab deruxtecan), Favezelimab + pembrolizumab, LUMAKRAS (sotorasib), among others.
-
The CRC market is expected to expand substantially due to rising disease prevalence and growing awareness. The launch of multiple late-stage pipeline therapies is also expected to significantly transform the market landscape during the forecast period.
Colorectal Cancer Overview
Colorectal cancer originates in the colon or rectum, often developing from precancerous polyps that gradually become malignant. It ranks among the most common cancers worldwide, with risk factors including age, family history, inflammatory bowel disease, and lifestyle habits such as high consumption of red and processed meats, physical inactivity, and smoking. Both inherited genetic mutations, such as those associated with Lynch syndrome, and acquired mutations play a central role in its development. The disease often progresses silently, with symptoms like changes in bowel habits, rectal bleeding, and abdominal pain typically emerging in later stages.
The delayed appearance of symptoms underscores the importance of regular screening, particularly for individuals at higher risk. Colorectal cancer not only has a high prevalence but also significantly impacts the physical and emotional well-being of patients and their families. Living with the disease often involves challenges that go beyond medical treatment, affecting psychological and social aspects of life.
Despite advances in molecular research that have improved prevention and treatment strategies, colorectal cancer remains a significant public health concern, necessitating continued awareness, research, and focused attention.
Get a Free sample for the Colorectal Cancer Market Forecast, Size & Share Analysis Report
Colorectal Cancer Epidemiology
The epidemiology section examines past, present, and projected trends in the seven major markets (7MM) from 2020 to 2034. It identifies the factors driving these trends through analysis of multiple studies and insights from key opinion leaders. Additionally, the section offers a detailed assessment of the diagnosed patient population and anticipated future developments.
Colorectal Cancer Epidemiology Segmentation:
The Colorectal Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Diagnosed Prevalence of Colorectal Cancer in Adults
-
Diagnosed Prevalence of Colorectal Cancer in Pediatrics
-
Diagnosed Prevalence of Colorectal Cancer by Types
-
Diagnosed Prevalence of Colorectal Cancer by Location
-
Diagnosed Prevalence of Colorectal Cancer by Severity
Download the report to understand which factors are driving Colorectal Cancer epidemiology trends
Colorectal Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section examines how quickly newly launched or soon-to-be-launched colorectal cancer therapies are being adopted in the market. This analysis includes drug-specific uptake, patient adoption by therapy type, and sales performance for each drug.
The therapeutics assessment section highlights the drugs with the fastest adoption rates and explores the factors driving their high utilization. It also provides a comparison of drugs based on market share.
Additionally, the report covers pipeline development activities in colorectal cancer, offering insights into therapeutic candidates at various stages and the key companies developing targeted treatments. It also reviews recent developments such as collaborations, mergers and acquisitions, licensing agreements, patent details, and other relevant information for emerging therapies.
Colorectal Cancer Therapies: FRUZAQLA (fruquintinib), TUKSYA (tucatinib), ENHERTU (trastuzumab deruxtecan), Favezelimab + pembrolizumab, LUMAKRAS (sotorasib)
Colorectal Cancer Key Companies: Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris Biotherapeutics
Discover more about therapies set to grab major Colorectal Cancer market share @ Colorectal Cancer Treatment Landscape
Colorectal Cancer Treatment Market
Several medications are available to manage the symptoms of colorectal cancer. For mild-to-moderate cases, topical therapies are commonly used to regulate gene transcription, slow cell proliferation, and promote keratinocyte differentiation. These treatments often include glucocorticoids, vitamin D analogs, and phototherapy.
Switching therapies is a routine and accepted strategy to enhance disease management and improve patient outcomes when initial treatments fail. However, this approach presents challenges. The guidelines for deciding when to switch therapies are often unclear, and there is limited data on transitioning between treatments in clinical practice. Some patients may also experience a worsening of symptoms after changing medications.
Another important consideration is the patient’s tolerance to the new therapy. Certain treatments can cause side effects or require close monitoring, making it necessary to switch if adverse effects occur or if the previous therapy becomes intolerable. Additionally, switching therapies can sometimes trigger the formation of antibodies against the medication, potentially reducing its effectiveness and limiting future treatment options.
Scope of the Colorectal Cancer Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Colorectal Cancer Companies: Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris Biotherapeutics, and others
-
Key Colorectal Cancer Therapies: FRUZAQLA (fruquintinib), TUKSYA (tucatinib), ENHERTU (trastuzumab deruxtecan), Favezelimab + pembrolizumab, LUMAKRAS (sotorasib), and others
-
Colorectal Cancer Therapeutic Assessment: Colorectal Cancer current marketed and Colorectal Cancer emerging therapies
-
Colorectal Cancer Market Dynamics: Colorectal Cancer market drivers and Colorectal Cancer market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Colorectal Cancer Unmet Needs, KOL’s views, Analyst’s views, Colorectal Cancer Market Access and Reimbursement
To know more about Colorectal Cancer companies working in the treatment market, visit @ Colorectal Cancer Clinical Trials and Therapeutic Assessment
Table of Contents
1. Colorectal Cancer Market Report Introduction
2. Executive Summary for Colorectal Cancer
3. SWOT analysis of Colorectal Cancer
4. Colorectal Cancer Patient Share (%) Overview at a Glance
5. Colorectal Cancer Market Overview at a Glance
6. Colorectal Cancer Disease Background and Overview
7. Colorectal Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Colorectal Cancer
9. Colorectal Cancer Current Treatment and Medical Practices
10. Colorectal Cancer Unmet Needs
11. Colorectal Cancer Emerging Therapies
12. Colorectal Cancer Market Outlook
13. Country-Wise Colorectal Cancer Market Analysis (2020–2034)
14. Colorectal Cancer Market Access and Reimbursement of Therapies
15. Colorectal Cancer Market Drivers
16. Colorectal Cancer Market Barriers
17. Colorectal Cancer Appendix
18. Colorectal Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Colorectal Cancer Pipeline
“Colorectal Cancer Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Colorectal Cancer market. A detailed picture of the Colorectal Cancer pipeline landscape is provided, which includes the disease overview and Colorectal Cancer treatment guidelines.
Colorectal Cancer Epidemiology
DelveInsight’s ‘Colorectal Cancer Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Colorectal Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/